© 2006 The Royal College of Psychiatrists
Schizophrenia, neuroleptic medication and mortality
Tampere School of Public Health, University of Tampere and Department of Psychiatry, Tampere University Hospital, Tampere
National Public Health Institute, Helsinki
Social Insurance Institution, Helsinki
National Research and Development Centre for Welfare and Health, Helsinki, Finland
Correspondence: Dr Matti Joukamaa, Department of Social Psychiatry, Tampere School of Public Health, University of Tampere, FIN-33014, Finland. E-mail: matti.joukamaa{at}uta.fi
See invited commentary, p.
128, this issue.
Background There is an excess of death from natural causes among people with schizophrenia.
Aims Schizophrenia and its treatment with neuroleptics were studied
for their prediction of mortality in a representative population sample of
7217 Finns aged 
30 years.
Method A comprehensive health examination was carried out at baseline. Schizophrenia was determined using the Present State Examination and previous medical records.
Results During a 17-year follow-up, 39 of the 99 people with schizophrenia died. Adjusted for age and gender, the relative mortality risk between those with schizophrenia and others was 2.84 (95% CI 2.06–3.90), and was 2.25 (95% CI1.61–3.15) after further adjusting for somatic diseases, bloodpressure, cholesterol, body mass index, smoking, exercise, alcohol intake and education. The number of neuroleptics used at the time of the baseline survey showed a graded relation to mortality. Adjusted for age, gender, somatic diseases and other potential risk factors for premature death, the relative risk was 2.50 (95% CI1.46–4.30) per increment of one neuroleptic.
Conclusions There is an urgent need to ascertain whether the high mortality in schizophrenia is attributable to the disorder itself or the antipsychotic medication.
Related articles in BJP:
- Highlights of this issue
- KIMBERLIE DEAN
BJP 2006 188: 105-a5.[Full Text] - Neuroleptics and mortality: a 50-year cycle: Invited commentary on.. .Schizophrenia, neuroleptic medication and mortality
- DAVID HEALY
BJP 2006 188: 128.[Full Text] - PETER TYRER
BJP 2006 188: 198.[Full Text]
This article has been cited by other articles:
 |
|
 |
|
  P. Tyrer From the Editor's desk. The British Journal of Psychiatry, August 1, 2009; 195(2): 188 - 188. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Baldessarini, L. H. Price, W. A. Ray, K. T. Murray, and C. M. Stein Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death N. Engl. J. Med., May 14, 2009; 360(20): 2136 - 2138. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Feeney Minimal - no, minimise - yes: INVITED COMMENTARY ON ... MINIMAL-MEDICATION APPROACHES TO TREATING SCHIZOPHRENIA Adv. Psychiatr. Treat., May 1, 2009; 15(3): 218 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Moncrieff Changing the balance of psychosis treatment: INVITED COMMENTARY ON ... MINIMAL-MEDICATION APPROACHES TO TREATING SCHIZOPHRENIA Adv. Psychiatr. Treat., May 1, 2009; 15(3): 221 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Healy Trussed in Evidence? Ambiguities at the Interface between Clinical Evidence and Clinical Practice Transcultural Psychiatry, March 1, 2009; 46(1): 16 - 37. [Abstract] [PDF]
|
|
|
|
|
|
K. Applbaum `Consumers are Patients!' Shared Decision-making and Treatment Non-compliance as Business Opportunity Transcultural Psychiatry, March 1, 2009; 46(1): 107 - 130. [Abstract] [PDF]
|
|
|
|
 |
|
 C. U. Correll, C. Rummel-Kluge, C. Corves, J. M. Kane, and S. Leucht Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials Schizophr Bull, March 1, 2009; 35(2): 443 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Taylor, P. Douglas-Hall, B. Olofinjana, E. Whiskey, and A. Thomas Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection The British Journal of Psychiatry, February 1, 2009; 194(2): 165 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Paton, T. R. E. Barnes, M.-R. Cavanagh, D. Taylor, P. Lelliott, and the POMH-UK project team High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing The British Journal of Psychiatry, June 1, 2008; 192(6): 435 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cormac, S. Hallford, L. Hart, S. Creasey, and M. Ferriter Evaluation of an integrated weight management and fitness programme in a high-security psychiatric setting Psychiatr. Bull., March 1, 2008; 32(3): 95 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. K. Hung and H. K. Cheung A survey of in-patient and out-patient antipsychotic prescriptions in Hong Kong Psychiatr. Bull., March 1, 2008; 32(3): 103 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tyrer From the Editor's desk The British Journal of Psychiatry, September 1, 2007; 191(3): 278 - 278. [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Gilmer, C. R. Dolder, D. P. Folsom, W. Mastin, and D. V. Jeste Antipsychotic Polypharmacy Trends Among Medi-Cal Beneficiaries With Schizophrenia in San Diego County, 1999-2004 Psychiatr Serv, July 1, 2007; 58(7): 1007 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Gill, S. E. Bronskill, S.-L. T. Normand, G. M. Anderson, K. Sykora, K. Lam, C. M. Bell, P. E. Lee, H. D. Fischer, N. Herrmann, et al. Antipsychotic Drug Use and Mortality in Older Adults with Dementia Ann Intern Med, June 5, 2007; 146(11): 775 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Dickerson, J. Boronow, C. Stallings, A. Origoni, and R. Yolken Toxoplasma gondii in Individuals With Schizophrenia: Association With Clinical and Demographic Factors and With Mortality Schizophr Bull, May 1, 2007; 33(3): 737 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Kreyenbuhl, M. Valenstein, J. F. McCarthy, D. Ganoczy, and F. C. Blow Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns Psychiatr Serv, April 1, 2007; 58(4): 489 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Ran, E. Y.-H. Chen, Y. Conwell, C. L.-W. Chan, P. S. F. Yip, M.-Z. Xiang, and E. D. Caine Mortality in people with schizophrenia in rural China: 10-year cohort study The British Journal of Psychiatry, March 1, 2007; 190(3): 237 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Leuci, L. Manenti, and C. Maggini Anti-phospholipid antibodies, neuroleptic treatment and cardiovascular morbidity The British Journal of Psychiatry, January 1, 2007; 190(1): 81 - 81. [Full Text] [PDF]
|
|
|
|
|
|
C. Gilleard Risk factors for coronary heart disease in people with severe mental illness The British Journal of Psychiatry, September 1, 2006; 189(3): 285 - 285. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Daniels Neuroleptics reconsidered. QJM, June 1, 2006; 99(6): 421 - 423. [Full Text] [PDF]
|
|
|
|
|
|
D. HEALY Neuroleptics and mortality: a 50-year cycle: Invited commentary on.. .Schizophrenia, neuroleptic medication and mortality The British Journal of Psychiatry, February 1, 2006; 188(2): 128 - 128. [Full Text] [PDF]
|
|
eLetters:
Read all eLetters
- A Sobering Thought
- Adil Y. Kadri, et al.
- BJP Online, 15 Feb 2006 [Full text]